Gyrolab Resources

Find technical documentation on our products as well as scientific references. 

In some browsers the download of PDFs requires that pop-up is allowed. Please contact if you are not able to view the PDF.

October 30, 2019
11:00 am Eastern Daylight Time (New York, GMT-04:00)

A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma


Mark Dysinger, M.S., Development Scientist III
Alexion Pharmaceuticals

Read more and register!

Rapid in-solution equilibrium approach to KD determination of biotherapeutic drug candidates
Recorded Webinar: Johan Engström, Senior Scientist at Gyros Protein Technologies, presents aspects of in-solution equilibrium affinity experiments using Gyrolab systems. 

Critical Reagent Characterization on Gyrolab using Solution Based Affinity Module: A Case Study
Recorded Webinar: Presenter Alison Joyce, Senior Principal Scientist, Biomedicine Design, Discovery Bioanalytical and Critical Reagent Group, Pfizer Inc. 

Redefining 3Rs for Safety Toxicology Biomarkers using Automated Nanoliter-scale Immunoassays
Recorded Webinar. Presenters: Diane Marie Hamlin, Investigative Toxicology, Eli Lilly and Wei Zheng, Immunoassays & Multiplexing, Bioscience, EMD Millipore. 

Fit-for-Purpose Biomarker Assay Development and Validation using Automated Nanoliter-Scale Immunoassays
Recorded Webinar. Presenters: Robert Durham, Ph.D., Gyros Inc., Chad A. Ray, PhD, Pfizer PDM, Kerry Oliver, Ph.D., Radix Biosolutions & Ariëlla Van de Sompel, Senior Research Associate, Ablynx. 

Rapid Reagent Screening and Characterization using Automated Nanoliter-scale Immunoassays
Recorded Webinar: Gyrolab is a reliable immunoassay platform that streamlines reagent selection and characterization during method development for biotherapeutics. Presenters: Frank Zambito, Research Scientist I, Bioanalytical Sciences, Bristol-Myers Squibb and Shawn Fernando, Senior Principal Researcher, Morphotek, Inc. 

Using Automated Nanoliter-Scale Immunoassays for Improved Performance and Efficiency
Recorded Webinar: Christophe Henry, Ph.D., Laboratory Head / Translational Medicine, Sanofi, presents case studies featuring reagent screening and method development for a variety of different biotherapeutics – traditional and non-conventional constructs. 

Assessing the immunogenicity of biopharmaceuticals
Recorded Webinar: Immunogenicity of therapeutic biopharmaceuticals can impact both the efficacy and the safety of the product. Assessment of anti-drug antibodies (ADAs) as well as neutralizing antibodies (NAbs) is a fundamental part of immunogenicity testing. Presenters: Cecilia Bill, Gyros Protein Technologies and Frida Pauly, Euro Diagnostica. 

Developing and Validating a Gyrolab ADA Assay to address drug tolerance and small sample volume
Recorded Webinar: Presenter Katrina Olson, Senior Associate Scientist, Pfizer, Andover. In this recorded webinar, Katrina describes the development of a Gyrolab bridging ADA assay, and the challenges that were surmounted in the development process. 

Development of sensitive ADA assays using automated acid dissociation in Gyrolab Mixing CD 96
In this webinar, Sarah Collomb from Novimmune SA will present an example of the development of a pre-clinical ADA assay using Gyrolab Mixing CD 96. 

Minimizing Repeats and Making Rapid Data Driven Decisions using Automated Nanoliter-scale Immunoassays for Impurity Testing in Bioprocess and Production
This recorded webinar focuses on the use of automated, nanoliter-scale flow-through technology to address a critical need for improved speed, throughput and reduced repeats in process related impurity testing. Presenters: Martha L. Jackson, Senior Research Scientist, Pfizer Inc. and Jun Hyuk Heo, Biochemist, Biotechnology New and Enabling Technologies (BNET), Merck & Co. 

Streamlined and automated immunoassays adapted for bioprocess workflows accelerate QbD strategy initiatives
Recorded Webinar: Presenter Daniel Forsström, application scientist at Gyros Protein Technologies  

Automated nanoliter-scale immunoassays to maximize productivity in bioprocess development
Recorded Webinar: Karolina Österlund, Manager Field Application Scientists EU and Asia, Gyros Protein Technologies AB, presents Gyrolab™ systems and a range of easy-to-use immunoassay kits as an automated, high-throughput platform for cell line and bioprocess development, illustrated by case studies from Shire, MedImmune and Merck. 

Gyrolab Generic PK Assay: Determination of Human IgG in Preclinical Matrices
Recorded Webinar: Daniel Forsström, Scientist at Gyros Protein Technologies, presents data using a high performance generic PK assay kit optimized for use with Gyrolab automated nanoliter-scale immunoassay systems.  

Automating Pharmacokinetic Bioanalysis at Nanoliter-Scale: Strategies for Development, Validation and Transfer
Recorded Webinar: “Detection of human IgG matrices: A universal approach”, Sufyan Maqbool, Associate Scientist I, Clinical Pharmacology and DMPK, MedImmune Cambridge UK and “Transfer and validation of a Gyrolab PK assay to a CRO”, Emilie Escoffier, MSc Biochemistry & Biotechnology, Research Assistant, Exploratory Science and,Translational Medicine, NovImmune SA, Geneva, Switzerland. 

Automated Pharmacokinetic Bioanalysis at Nanoliter-Scale: From Early Stage Development to Validation and Transfer for Clinical Studies
Recorded webinar focusing on the implementation of the Gyrolab workstation for automated PK bioanalysis in support of early stage development, regulated bioanalysis and clinical trials. Presenters: Vimal Patel, Senior Associate Scientist, Amgen, Thousand Oaks, CA, USA, Jo Goodman, Senior R&D Manager, MedImmune, Cambridge, UK, and Shawn Fernando, Senior Researcher, Bioanalytical Development, Morphotek, Exton, PA, USA. 

Challenges of supporting multiple programs for PK Bioanalysis: a CRO perspective
Recorded Webinar: Contract Research Organisations (such as Envigo) are required to transfer, develop, validate and carry out sample analysis on a wide range of drug products from clients. Discussed are various aspects that must be considered when choosing a suitable assay platform for pharmacokinetic (PK) studies. Presenter: Deborah McManus Senior Technical Specialist in the Department of Biomarkers, Bioanalysis and Clinical, Envigo UK. 

Overcoming Disease Specific Matrix Effects in a Clinical Pharmacokinetic Assay
Recorded Webinar. Presenter Kathi J. Williams, Senior Scientific Researcher Assay Development and Technology, Genentech, Inc 

Streamlining product titer using automated nanoliter-scale immunoassays with throughput, dynamic range & reliable reproducibility
Recorded Webinar. Presenters: Matt Traylor, Analytical Development, Shire Human Genetic Therapies, “Rapid Development of Gyrolab Titer ELISAs to Support Biopharmaceutical Process Development” and Jun Heo, Analytical Scientist, Bioprocess Technology and Expression (BTE), Merck & Co., Inc., “High Throughput Monoclonal Antibody Titer Assay for BioProcess Development”.